Avid Bioservices Inc (CDMO)

[north40000]

Does MRK prove the truth of the statement that, if you can have[or already have] the initial ability to pre-select the correct patient to treat[e.g., a patient with enough targets to hit with your company's I-O therapy], the company having that initial ability will achieve a better share of successful treatments:

http://finance.yahoo.com/news/merck-keytruda-pembrolizumab-demonstrates-superior-104500135.html

"... Patients enrolled were those who had received no prior systemic chemotherapy treatment for their advanced disease and whose tumors expressed high levels of PD-L1 (defined as a tumor proportion score of 50 percent or more) as determined by a central laboratory using an immunohistochemistry assay...."

Failing that initial ability, Keytruda still likely fails treatment purpose because of low RRRs, w/o assistance from somewhere to overcome those patients' disadvantage.

Read the entire article for context.

See also jakedogman's post of:

http://www.fiercebiotech.com/biotech/merck-bristol-showdown-awaits-as-keytruda-lung-cancer-trial-stopped-strong-results

for less rationale as to how patients were predetermined, pre-selected.